WEIGAO GROUP (01066) plans to establish a fund to invest in small and medium-sized enterprises and medium-sized enterprises in South Korea and overseas.

WEIGAO GROUP (01066) announced that on April 30, 2026, the company's indirect wholly-owned subsidiary, Wego Healthcare Fund (as a limited partner), has entered into a limited partnership agreement with Weigao (Hong Kong) (as a general partner) to establish a fund with a planned size of 52.965 billion Korean Won (equivalent to approximately 2.436 billion RMB). The fund will mainly invest in small and medium-sized enterprises and medium-sized enterprises in Korea and overseas, focusing on open innovation and overseas business expansion in Korea and overseas companies, universities, and research institutions. The proposed commitment of Wegao Healthcare Fund will reach 15.89 billion Korean Won (equivalent to approximately 73.09 million RMB), accounting for 30% of the total committed investment of the fund. The Board of Directors believes that as a leading enterprise in the Chinese medical device industry, international expansion and technological innovation are crucial for the company to continuously improve its industry competitiveness. The limited partnership agreement aims to strengthen the group's global business layout, enhance product innovation capabilities, and expand access to overseas markets. The main investment scope and regions of the fund are highly compatible with the company's development strategy of deepening research and development innovation, accelerating technology platform construction, expanding complementary product lines, and exploring global market channels. Participating in the fund as a limited partner will enable the company to gain access to potential Asia-Pacific and international technology platforms early, as well as dynamic and cooperative opportunities in innovative enterprises guided by clinical value, enriching the group's product pipeline, acquiring innovative technologies in a cost-effective manner, and accelerating entry into new markets. In addition, this investment has considerable long-term return potential that matches the characteristics of venture capital risks. The fund adopts a dual executive partner structure, jointly served by SV Investment and Weigao (Hong Kong) (a subsidiary of Weigao Group), fully leveraging the local industry network, policy resources, and rich investment experience of the general partner in Korea. The other limited partners of the fund are leading enterprises in their respective industries, with quality resource networks in Korea and international markets. The company believes that participating in the fund can effectively utilize existing financial resources, enhance potential capital gains, accumulate rich industry resources, and leverage the advantages of local general partners to quickly enter key markets such as Korea, North America, and Southeast Asia, thus enhancing its international operational capabilities. Additionally, approximately half of the fund's investments will be allocated to Korea and the other half to other overseas regions, which helps to diversify risks from market cyclic fluctuations.